Rebif Market Position Safe Due To Tysabri Reimbursement Concerns – Serono
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono exec cites several hiccups to the uptake of Elan/Biogen Idec's multiple sclerosis therapy Tysabri, including reimbursement concerns and premium price. Global sales for Pfizer/Serono's Rebif reached the $1 bil. mark last year.